Skip to main content

Table 1 Baseline demographic and disease characteristics

From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Demographic or disease characteristic Number of subjects (N = 48)
Sex, n (%)  
 Female 21 (44)
 Male 27 (56)
Race, n (%)  
 White 33 (69)
 Nonwhite 15 (31)
  Asian 1 (2)
  Black or African American 13 (27)
  Multiracial 1 (2)
Age, years  
 Mean (standard deviation) 61.6 (11.2)
 Median 62
 Range 39–81
Age, n (%)  
 18–64 years 30 (63)
 ≥65 years 18 (38)
ECOG performance status, n (%)  
 0 12 (25)
 1 31 (65)
 2 5 (10)
Prior chemotherapy regimens, n (%)  
 ≤2 16 (33)
 3–5 23 (48)
 ≥6 9 (19)
Cancer type, n  
 Colorectal 15
 NSCLC 5
 Ovarian 4
 Breast, melanoma 3 each
 Prostate, cholangiocarcinoma, adenoid cystic, sarcoma, pancreatic, neuroendocrine 2 each
 Esophageal, gastric, gastrointestinal stromal tumor, hepatocellular, pseudomyxoma peritonei, vulvar 1 each